TWST
Twist Bioscience Corp Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$152.78Close
$9.3BMarket cap
$25.45 – $205.0052-week range
Nov 12, 2026Next report · before the open
Highlights
Strengths
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, over 25% off the high
- Far from its high 25% below its 52-week high
- Earnings shrinking EPS −268% year on year
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
25%
1wk
up 9.2%
price change
1mo
down 20.9%
price change
12-month return
up 390%
market up 11% ·
its own up 363%
F-score
5 / 9
Mixed
Altman Z
30.37
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
19.6×
price / book
Earnings yield
down 1.5%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
up 20%
year on year
EPS growth
down 268%
latest quarter
Sales growth
up 23%
latest quarter · +4 pts
ROE
down 16%
return on equity
Free cash margin
down 20%
-$75.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- short-term liquidity weakened
- issued more shares
- profitability improving
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- Gross margin 42.6% → 50.7%
Trade setup
ATR%
9.8%
$15.03 a day · 2×ATR $122.73
RS
99 / 99
vs the universe
Trend
6 / 8
under the 50-day, over 25% off the high
Relative volume
1.4×
vs 50-day average
Up/down volume
0.84
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- Within 25% of the 52-week high: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 3.0% over the year, from 59m to 61m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 3, 2026
Last shock
Oct 6, 2026-19% in one session4.0× volumeno filing matched-8% since
Financials
- Gross 51%
- Net -21%
- Free cash -20%
- Cash
- Long-term debt
| FY2020Sep 30, 2020 | FY2021Sep 30, 2021 | FY2022Sep 30, 2022 | FY2023Sep 30, 2023 | FY2024Sep 30, 2024 | FY2025Sep 30, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $90.1M | $132.3M | $203.6M | $245.1M | $313.0M | $376.6M |
| Gross margin | 32% | 39% | 41% | 37% | 43% | 51% |
| Operating income | -$140.1M | -$152.7M | -$234.8M | -$217.2M | -$220.8M | -$136.3M |
| Net income | -$139.9M | -$152.1M | -$217.9M | -$204.6M | -$208.7M | -$77.7M |
| Net margin | -155% | -115% | -107% | -83% | -67% | -21% |
| Earnings per share | -$3.57 | -$3.15 | -$4.04 | -$3.60 | -$3.60 | -$1.30 |
| Free cash flow | -$152.1M | -$139.3M | -$226.2M | -$170.3M | -$69.2M | -$75.6M |
| Free cash margin | -169% | -105% | -111% | -69% | -22% | -20% |
| Cash | $93.7M | $465.8M | $378.7M | $286.5M | $226.3M | $183.0M |
| Long-term debt | $1.4M | $833,000 | — | — | — | — |
| Shareholders' equity | $336.3M | $580.8M | $789.4M | $623.4M | $472.7M | $473.0M |
| Shares outstanding | 45.08m | 49.50m | 56.52m | 57.56m | 58.88m | 60.63m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 3, 2026 | Quarterly ↗ | Jun 30, 2026 | 34d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Feb 2, 2026 | Quarterly ↗ | Dec 31, 2025 | 33d |
| Nov 17, 2025 | Annual ↗ | Sep 30, 2025 | 48d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Feb 3, 2025 | Quarterly ↗ | Dec 31, 2024 | 34d |
| Nov 18, 2024 | Annual ↗ | Sep 30, 2024 | 49d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 2, 2024 | Quarterly ↗ | Dec 31, 2023 | 33d |
| Nov 21, 2023 | Annual ↗ | Sep 30, 2023 | 52d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 19, 2026 | Regulation FD ↗ |
| Aug 19, 2026 | Other events ↗ |
| Aug 5, 2026 | Material agreement · Regulation FD ↗ |
| Aug 3, 2026 | Results ↗ |
| May 4, 2026 | Results ↗ |
| Feb 17, 2026 | Unregistered share sale · Other events ↗ |
| Feb 6, 2026 | Shareholder vote ↗ |
| Feb 2, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Nov 14, 2025 | Results ↗ |
| Aug 6, 2025 | Director or officer change ↗ |
| Aug 4, 2025 | Results ↗ |